Aspen Neuroscience Inc ASPE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $13.04
- Day Range
- $12.00–12.97
- 52-Week Range
- $11.69–14.53
- Bid/Ask
- $12.00 / $12.01
- Shares Outstanding
- 29.08M
- Market Cap
- $348.95M
- Volume/Avg
- 132,376 / 959,648
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson’s disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
Valuation
|
Metric
|
ASPE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASPE
|
|---|---|
Quick Ratio | 4.43 |
Current Ratio | 4.56 |
Interest Coverage | — |
Quick Ratio
ASPE
Profitability
|
Metric
|
ASPE
|
|---|---|
Return on Assets (Normalized) | −47.45% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ASPE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|KCl%^tS | LOCK|@>>% | $140B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%?WjWjw | LOCK|!kYLS | $99B | |||
| Moderna Inc
MRNA
| LOCK|Z!@D@?G | LOCK|Rg | $88B | |||
| argenx SE ADR
ARGX
| LOCK|#^<sS^ | LOCK|>C | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>z#bP@ | LOCK|Lt | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Kf!SpVT? | LOCK|!P>vv | $30B | |||
| Incyte Corp
INCY
| LOCK|V??FtC | LOCK|<< | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Mc>F$$ | LOCK|S# | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|G!$wtJ | LOCK|&hBWl | $21B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|jZ@!RDK | LOCK|N&w | $15B |
United States